The State of Research on PD1/PD-L1 Regulation by Non-coding RNA in Non-small Cell Lung Cancer

Ruohan Fan

doi:10.62051/ijphmr.v2n2.13

Authors

Ruohan Fan

DOI:

https://doi.org/10.62051/ijphmr.v2n2.13

Keywords:

Non-small cell lung cancer, PD-1/PD-L1, Immune checkpoint inhibitors, Non-coding RNA, Immunotherapy

Abstract

Globally, non-small cell lung cancer (NSCLC) is the primary cause of death from cancer. Immunotherapy has advanced significantly in the medical management of NSCLC over the previous couple of decades. Particularly immune checkpoint drugs that target programmed death receptor 1 (PD-1) and its ligand 1 (PD-L1). Meanwhile, miRNAs are crucial for controlling the PD-1/PD-L1 pathway in NSCLC and are an increasingly significant field of investigation at the moment. For these reasons, this paper reviewed the mechanism of the PD-1/PD-L1 pathway in immunological escape from malignant cells and explored how non-coding RNAs (including microRNAs, long-chain non-coding RNAs, and cyclic RNAs) can affect the occurrence as well as growth of NSCLC by regulating PD-1/PD-L1 activity. Argument cites specific miRNAs such as miRNA-200c have the capability to alter the level of PD-L1 expression and thus enhance cancer innate immunity. Beyond that, LncRNA such as NEAT1 affect expression of PD-L1 and evasion of the body's defenses through interaction with miRNAs. In NSCLC, circular RNAs are performing a crucial function in evading immune responses. The article also discusses the efficacy and challenges of our self-developed PD-1 inhibitors in treating advanced NSCLC and emphasizes the need to improve the precision of immunotherapy. Finally, the article highlights the necessity for additional investigation to uncover more upstream modulators to enhance the prognosis and clinical outcomes of NSCLC individuals.

References

[1] Haanen, J. B., Robert, C. (2015). Immune checkpoint inhibitors. Immuno-Oncology, 42: 55-66.

[2] Salmaninejad, A., Valilou, S. F., Shabgah, A. G., et al. (2019). PD‐1/PD‐L1 pathway: basic biology and role in cancer immunotherapy. Journal of cellular physiology, 234(10): 16824-16837.

[3] Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer, 12(4): 252-264.

[4] Chauvin, J. M., Pagliano, O., Fourcade, J., et al. (2015). TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients. The Journal of clinical investigation, 125(5): 2046-2058.

[5] Yang, Y., Chen, W., Ma, J., Duan, L. (2024). Comparative efficacy and safety of PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced nonsquamous non-small cell lung cancer: A network meta-analysis. Clinical Thoracic and Cardiovascular Surgery. https://oversea.cnki.net/kns/Detail?sfield=fn&QueryID=0&CurRec=1&recid=&FileName=ZXYX20240320001&DbName=CAPJLAST&DbCode=CAPJ&yx=Y&pr=&URLID=51.1492.R.20240416.1153.010

[6] Li, X., Yang, L., Chen, L. L. (2018). The Biogenesis, Functions, and Challenges of Circular RNAs. Molecular cell, 71(3): 428–442.

[7] Calin, G. A., Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature reviews cancer., 6(11): 857-866.

[8] Hussen, B. M., Hidayat, H. J., Salihi, A., et al. (2021). MicroRNA: A signature for cancer progression. Biomedicine & Pharmacotherapy, 138: 111528.

[9] Segal, M., Slack, F. J. (2020). Challenges identifying efficacious miRNA therapeutics for cancer. Expert opinion on drug discovery, 15(9): 987-991.

[10] Zhang, Q., Pan, J., Xiong, D., Zheng, J., et al. (2023). Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention. Frontiers in immunology, 14: 1166951.

[11] Ricciuti, B., Mencaroni, C., Paglialunga, L., et al. (2016). Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical oncology, 33: 1-12.

[12] Hu, Q., Ma, H., Chen, H., et al. (2022). LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside. Cell death discovery, 8(1): 359.

[13] Zhao, M. M., Ge, L. Y., Yang, L. F., et al. (2020). LncRNA NEAT1/miR-204/NUAK1 axis is a potential therapeutic target for non-small cell lung cancer. Cancer management and research, 13357-13368.

[14] Zhao, H., Li, B., Zheng, F., et al. (2024). Effects of LncRNA NEAT1 on proliferation, apoptosis, and PD-1/PD-L1 expression in non-small cell lung cancer cells through miR-128-3p/HNRNPL axis. Modern Immunology, 02: 141-151.

[15] Katopodi, T., Petanidis, S., Domvri, K, et al. (2021). Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3/PTK2 immunosuppressive circuit. Scientific reports, 11(1): 15455.

[16] Pei, X., Chen, S. W., Long, X., et al. (2020). circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis. Aging, 12(13): 13038–13058.

[17] Li, B., Zhu, L., Lu, C., et al. (2021). circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nature communications, 12(1): 295.

[18] Chen, S. W., Zhu, S. Q., Pei, X., et al. (2021). Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Molecular cancer, 20(1): 144.